Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen ...
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing ...
(RTTNews) - Viridian Therapeutics (VRDN) Monday has granted 113,200 stock options to nine new employees and 310,700 stock options to newly appointed Chief Medical Officer, Dr. Radhika Tripuraneni.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback